Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katja Deterding

Showing results (81-90 of 98) with videos related to

Pageof 10
Sort By:
Antiviral Therapy|March 27, 2009
Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatmentAndreas Erhardt, Katja Deterding, Yves Benhamou, et al.
Hepatology (Baltimore, Md.)|March 13, 2024
Safety and efficacy of off-label bulevirtide monotherapy in patients with HDV with decompensated Child-B cirrhosis-A real-world case seriesChristopher Dietz-Fricke, Elisabetta Degasperi, Mathias Jachs, et al.
Hepatology (Baltimore, Md.)|May 13, 2011
Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological responseRoeland Zoutendijk, Jurriën G P Reijnders, Ashley Brown, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 18, 2025
Impact of Handling Perception and Language Barriers on Virologic Response to Daily Subcutaneous Bulevirtide in Hepatitis DToni Herta, Christopher Dietz-Fricke, Münevver Demir, et al.
JHEP Reports : Innovation in Hepatology|February 12, 2026
Treatment response to bulevirtide is linked to amelioration of portal hypertension in patients with chronic hepatitis DLisa Sandmann, Mathias Jachs, Tammo L Tergast, et al.
Journal of Medical Virology|August 21, 2008
Prevalence of HBV genotypes in Central and Eastern EuropeKatja Deterding, Ileana Constantinescu, Filofteia Daniela Nedelcu, et al.
European Journal of Gastroenterology & Hepatology|November 18, 2015
Symptoms of anxiety and depression are frequent in patients with acute hepatitis C and are not associated with disease severityKatja Deterding, Norbert Grüner, Peter Buggisch, et al.
The Lancet. Infectious Diseases|March 26, 2013
Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trialKatja Deterding, Norbert Grüner, Peter Buggisch, et al.
Hepatology (Baltimore, Md.)|December 10, 2009
Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analoguesFlorian van Bömmel, Robert A de Man, Heiner Wedemeyer, et al.
Journal of Gastroenterology and Hepatology|March 25, 2016
Flares during long-term entecavir therapy in chronic hepatitis BHeng Chi, Pauline Arends, Jurriën G P Reijnders, et al.
Pageof 10

Showing results (81-90 of 98) with videos related to

Sort By:
Pageof 10
Antiviral Therapy|March 27, 2009
Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatmentAndreas Erhardt, Katja Deterding, Yves Benhamou, et al.
Hepatology (Baltimore, Md.)|March 13, 2024
Safety and efficacy of off-label bulevirtide monotherapy in patients with HDV with decompensated Child-B cirrhosis-A real-world case seriesChristopher Dietz-Fricke, Elisabetta Degasperi, Mathias Jachs, et al.
Hepatology (Baltimore, Md.)|May 13, 2011
Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological responseRoeland Zoutendijk, Jurriën G P Reijnders, Ashley Brown, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 18, 2025
Impact of Handling Perception and Language Barriers on Virologic Response to Daily Subcutaneous Bulevirtide in Hepatitis DToni Herta, Christopher Dietz-Fricke, Münevver Demir, et al.
JHEP Reports : Innovation in Hepatology|February 12, 2026
Treatment response to bulevirtide is linked to amelioration of portal hypertension in patients with chronic hepatitis DLisa Sandmann, Mathias Jachs, Tammo L Tergast, et al.
Journal of Medical Virology|August 21, 2008
Prevalence of HBV genotypes in Central and Eastern EuropeKatja Deterding, Ileana Constantinescu, Filofteia Daniela Nedelcu, et al.
European Journal of Gastroenterology & Hepatology|November 18, 2015
Symptoms of anxiety and depression are frequent in patients with acute hepatitis C and are not associated with disease severityKatja Deterding, Norbert Grüner, Peter Buggisch, et al.
The Lancet. Infectious Diseases|March 26, 2013
Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trialKatja Deterding, Norbert Grüner, Peter Buggisch, et al.
Hepatology (Baltimore, Md.)|December 10, 2009
Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analoguesFlorian van Bömmel, Robert A de Man, Heiner Wedemeyer, et al.
Journal of Gastroenterology and Hepatology|March 25, 2016
Flares during long-term entecavir therapy in chronic hepatitis BHeng Chi, Pauline Arends, Jurriën G P Reijnders, et al.
Pageof 10